|
Some of the other noteworthy trials in HER2 positive disease include a phase II randomized controlled trial of a new oral HER2 inhibitor, tucatinib, in combination with trastuzumab and capecitabine NCT02614794 <a href=https://stromectol.ink/>stromectol over the counter uk</a> Safdari F, Motaghi Dastenaei B, Kheiri S, Karimiankakolaki Z |
|
转播